Germline BRCA1/2 mutations and p27Kip1 protein levels independently predict outcome after breast cancer

Journal of Clinical Oncology

Volumn 18, Issue 24, 2000, Pages 4045-4052

  Chappuis, P O ^a   Kapusta, L ^a   Begin L R ^a   Wong, N ^a   Brunet, J S ^a   Narod, S A ^a   Slingerland, J ^a   Foulkes, W D ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; KIP1 PROTEIN; PROTEIN P27; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRCA2 GENE; BREAST CANCER; CANCER SURVIVAL; FEMALE; FOLLOW UP; FOUNDER EFFECT; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JEW; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

EID: 0034671186     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.24.4045     Document Type: Article

References (45)

1. Prognostic factors and treatment decisions in axillary-node-negative breast cancer
2. Tumor-related prognostic factors for breast cancer
3. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
4. CDK inhibitors: Positive and negative regulators of G1-phase progression
5. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer
6. p27/Kip1 mutation found in breast cancer
7. Moving protein heads for breakdown
8. Regulation of the Cdk inhibitor p27 and its deregulation in cancer
9. Kip1
10. Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients
11. Kip1 protein: Prognostic implications in primary breast cancer
12. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas
13. kip1 in node-positive breast cancer
14. Kip1 and apoptosis in human breast cancer
15. p27 expression as a prognostic factor of breast cancer in Taiwan
16. BRCA1 and BRCA2: From molecular genetics to clinical medicine
17. Breast Cancer Linkage Consortium: Pathology of familial breast cancer: Differences between breast cancers in carriers of BRCA1 and BRCA2 mutations and sporadic cases
18. Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage
19. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations
20. p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours
21. The influence of familial and hereditary factors on the prognosis of breast cancer
22. Breast carcinomas arising in carriers of mutations in BRCA1 or BRCA2: Are they prognostically different?
23. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations
24. Survival and tumor characteristics of German hereditary breast cancer patients
25. Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer
26. Worse survival among breast cancer patients in families carrying the BRCA2 susceptibility gene
27. Survival in hereditary breast cancer associated with germline mutations of BRCA2
28. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families
29. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
30. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer
31. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast cancers in Ashkenazi Jewish women
32. Deregulated expression of p27(Kip1) in human breast cancers
33. Kip1 expression and interaction with other cell cycle-associated proteins in mammary carcinoma
34. Ansquer A, Gautier C, Fourquet A, et al: Survival in early-onset BRCA1 breast-cancer patients
35. Familial invasive breast cancers: Worse outcome related to BRCA1 mutations
36. Prognosis and clinical presentation of BRCA2-associated breast cancer
37. BRCA-associated breast cancer: Absence of a characteristic immunophenotype
38. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/Cip1
39. Kip1 protein is associated with poor clinical outcome of breast cancer patients treated with systemic chemotherapy and is linked to cell proliferation and differentiation
40. Cancer-susceptibility genes. Gatekeepers and caretakers
41. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations
42. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation
43. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F
44. Kip1 is haplo-insufficient for tumour suppression
45. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases